Boston Scientific Corporation (ETR:BSX)
Market Cap | 132.46B |
Revenue (ttm) | 16.24B |
Net Income (ttm) | 1.88B |
Shares Out | n/a |
EPS (ttm) | 1.27 |
PE Ratio | 70.46 |
Forward PE | 35.04 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | n/a |
Average Volume | 240 |
Open | 88.80 |
Previous Close | 88.00 |
Day's Range | 87.60 - 88.80 |
52-Week Range | 62.00 - 105.00 |
Beta | n/a |
RSI | 46.56 |
Earnings Date | Jul 23, 2025 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews

I'm Buying Dividend Aristocrats At Bargain Basement Prices
Now is an opportune time to focus on income stocks like that offer value and stability amid market volatility. I focus on 2 Dividend Aristocrats that are attractively valued while supporting well-cove...
S&P 500 Surges 1%; New York Manufacturing Activity Tumbles In June
U.S. stocks traded higher midway through trading, with the S&P 500 gaining around 1% on Monday. The Dow traded up 0.80% to 42,536.72 while the NASDAQ climbed 1.51% to 19,699.21. The S&P 500 also rose,...

What's Happening With Boston Scientific Stock?
Boston Scientific (NYSE:BSX) has experienced a stock price increase of over 30% in the last twelve months, greatly exceeding the S&P 500's gain of 9%. This remarkable performance can be credited to th...

US Stocks Higher; Dow Jumps Over 400 Points
U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 400 points on Monday. Following the market opening Monday, the Dow traded up 1.02% to 42,629.20 while the NASDAQ clim...

This Boston Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag...

$100 Invested In Boston Scientific 10 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 10 years by 7.78% on an annualized basis producing an average annual return of 18.87%. Currently, Boston Scientific has a marke...

20 stocks bucking bad trends on Wall Street — what might be next for them?
Analysts have been cutting their estimates for companies' sales and profits, but there are always exceptions to trends.

3 Growth Stocks That Aren't the Magnificent 7
Growth-oriented investors have been able to operate on autopilot, but tomorrow's winners might not look like yesterday's.
Is Boston Scientific Gaining or Losing Market Support?
Boston Scientific's (NYSE: BSX) short percent of float has risen 6.6% since its last report. The company recently reported that it has 16.75 million shares sold short , which is 1.13% of all regular ...

P/E Ratio Insights for Boston Scientific
In the current market session, Boston Scientific Inc. (NYSE: BSX) stock price is at $104.20, after a 0.29% drop. However, over the past month, the company's stock increased by 0.10% , and in the past...
Boston Scientific: Old, Reliable; Buy For Their Consistent Growth
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empire
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Boston Scientific Corporation (NYSE: BSX) is pulling the plug on its ACURATE neo2 and Prime aortic valve systems . What Happened : The medical technology giant halted global sales and abandoned regul...

Boston Scientific Scraps This Aortic Valve, Sticks To 2025 Outlook
Boston Scientific Corporation BSX is pulling the plug on its ACURATE neo2 and Prime aortic valve systems.
Boston Scientific Corporation (BSX) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
How Boston Scientific's Surprise Setback Bolstered Edwards, Medtronic, Abbott
Edwards Lifesciences stock jumped Wednesday after Boston Scientific said it would stop selling its rival heart-valve replacement systems.
Edwards Lifesciences, Medtronic gain as Boston Scientific pulls aortic valve systems

Boston Scientific to not seek US approval for heart device amid regulatory challenges
Boston Scientific said on Wednesday it will stop pursuing U.S. approval for its experimental heart device due to increased clinical and regulatory requirements.

$1000 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.95% on an annualized basis producing an average annual return of 21.03%. Currently, Boston Scientific has a marke...
Boston Scientific Corporation (BSX) Bank of America's 2025 Health Care Conference (Transcript)
Boston Scientific Stock Flirts With A Buy Point, Once Again
Boston Scientific stock is wavering around the buy point of a double-bottom base. The company recently raised its 2025 earnings outlook.

$100 Invested In Boston Scientific 15 Years Ago Would Be Worth This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 15 years by 8.98% on an annualized basis producing an average annual return of 20.36%. Currently, Boston Scientific has a marke...

Boston Scientific announces upcoming investor conference schedule
MARLBOROUGH, Mass. , May 1, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences in May.

Baron Health Care Fund Q1 2025 Top Contributors And Detractors
Boston Scientific's shares rose due to strong market growth, innovative products like pulsed field ablation, and disciplined cost management, driving double-digit EPS growth. Vertex Pharmaceuticals sa...

Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints
Trial achieves positive results in the treatment of persistent atrial fibrillation MARLBOROUGH, Mass. and SAN DIEGO , April 24, 2025 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today ann...